Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.97 EUR
Change Today +0.19 / 6.83%
Volume 612.5K
TNG On Other Exchanges
EN Paris
As of 10:39 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

transgene sa (TNG) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/9/14 - €8.12
52 Week Low
10/2/15 - €2.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TRANSGENE SA (TNG)

Related News

No related news articles were found.

transgene sa (TNG) Related Businessweek News

No Related Businessweek News Found

transgene sa (TNG) Details

Transgene S.A., a biopharmaceutical company, engages in the research, design, development, and manufacture of therapeutic vaccines and immunotherapeutic products to treat cancers and chronic infectious diseases. Its principal products under Phase II clinical trials include TG4010 for the treatment of metastatic non-small cell lung cancer in combination with chemotherapy; Pexa-Vec primarily for the treatment for liver cancer; TG4001, a therapeutic vaccine for oropharyngeal cancer caused by an infection by the human papilloma virus (HPV); and TG4040 for the treatment of chronic hepatitis C. The company has agreements with Novartis for the development of TG4010 to treat various cancers; Jennerex Biotherapeutics, Inc. for the development and marketing of Pexa-Vec, an oncolytic product; and European Organization for Research and Treatment of Cancer for the development of TG4001 to treat HPV induced head and neck cancers. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene S.A. operates as a subsidiary of Institut Mérieux SA.

266 Employees
Last Reported Date: 04/29/15
Founded in 1979

transgene sa (TNG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €72.2K
Vice President of Quality and Qualified Pharm...
Total Annual Compensation: €124.2K
Compensation as of Fiscal Year 2014.

transgene sa (TNG) Key Developments

Transgene Sa Reports IFRS Unaudited Consolidated Earnings Results for the First Six Months Ended June 30, 2015; Revises Cash Burn Guidance for 2015

Transgene SA reported IFRS unaudited consolidated earnings results for the first six months ended June 30, 2015. For the period, the company reported revenue of EUR 5,255,000 against EUR 6,074,000 a year ago. Operating loss was EUR 20,179,000 against EUR 19,812,000 a year ago. Loss before tax was EUR 21,659,000 against EUR 21,133,000 a year ago. Net loss from continuing operations was EUR 21,659,000 against EUR 21,133,000 a year ago. Net loss was EUR 28,083,000 against EUR 25,113,000 a year ago. Diluted loss per share was EUR 0.73 against EUR 0.65 a year ago. Net cash used in operating activities was EUR 19,812,000 against EUR 23,821,000 a year ago. Acquisition of property, plant and equipment was EUR 578,000 against EUR 831,000 a year ago. Acquisition of intangible assets was EUR 4,000 against EUR 97,000 a year ago. The company has revised its guidance for cash burn for the full year 2015 to EUR 35 million EUR 40 million, a significant reduction compared to previous guidance of approximately EUR 45 million. The reasons for the change are: a cost reduction plan implemented in parallel to the restructuring plan.

Transgene SA Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

Transgene SA announced the presentation by Dr. Elisabeth Quoix of final data from the Phase 2b part of the TIME trial with TG4010 MUC1 targeted immunotherapy in non-small cell lung cancer (NSCLC) at the 16th World Conference on Lung Cancer in Denver, CO, USA. The overall survival (OS) data confirm the strength of previously reported improvements and are significant in patients with a low level of triple positive activated lymphocytes (TrPAL2), as well as in those patients with low TrPAL and non-squamous disease. The TIME trial is a randomized, double-blind, placebo-controlled study evaluating TG4010 in combination with chemotherapy in the first-line treatment of advanced (Stage IV) NSCLC patients. A total of 222 patients were enrolled in the Phase 2b portion of the trial. The primary objective of the Phase 2b part of the study was to analyze progression-free survival (PFS); OS, response rate, duration of response and the safety of TG4010 in combination with chemotherapy were also assessed. Data presented indicated that patients with low levels of TrPAL at baseline showed statistically significant differences in both PFS and OS when treated with TG4010 compared to placebo; a higher response rate and duration of response two times longer than the placebo group were also observed. These improvements were even more notable in the subgroup of patients with both non-squamous disease and low levels of TrPAL. In this important subgroup of patients, 40% were still alive at 24 months in the group treated with TG4010 plus chemotherapy compared to 19% in the control group. In addition, as previously reported, clear activity was also seen with TG4010 in patients having low levels (<5%) of tumor cells expressing PD-L1. PD-L1 (programmed death-ligand 1) is a protein that is believed to play a major role in suppressing the immune system and is an important target for cancer treatment. TG4010 was well tolerated, and the nature and incidence of adverse events in the TG4010 arm were consistent with previous Phase 2 clinical trials. The most frequent TG4010-related adverse events were mild to moderate injection site reactions. To date, over 350 patients have been treated with TG4010. Further development of TG4010 in NSCLC is planned in combination with chemotherapy and with immune checkpoint inhibitors, such as anti-PDL1 and anti-PD1 inhibitors.

Transgene SA Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 01:00 PM

Transgene SA Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 01:00 PM. Venue: Sofitel Hotel, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNG:FP €2.97 EUR +0.19

TNG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $5.72 USD -0.26
Genocea Biosciences Inc $6.30 USD +0.125
GenVec Inc $2.04 USD +0.02
Inovio Pharmaceuticals Inc $6.06 USD +0.10
Vical Inc $0.44 USD +0.002
View Industry Companies

Industry Analysis


Industry Average

Valuation TNG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at